| Learn more about its compact packaging and bleed control. |
View online |
|
|
|
 |
| Indicated for congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelets, and acquired hemophilia. See full indication below. |
|
|
|
| Success Speaks for Itself | Pharmacy Series |
| Your team is counting on you: |
| Be prepared with NovoSeven® RT |
| NovoSeven® RT provides rapid administration and effective bleed control across the broadest range of patients with bleeding disorders as compared to FEIBA®, OBIZUR®, and SEVENFACT®.1-5,a |
|
| Designed with the needs of hospital pharmacies in mind: |
|
 |
| Designed with the needs of hospital pharmacies in mind: |
|
 |
| Low-volume dosing and compact packaging maximizes space compared to pd-aPCC1,3 |
|
|
|
| 16x less infusion volume compared with pd-aPCC1,3,b |
|
|
|
| Ability to administer via continuous infusion for perioperative management1 |
|
|
| Room temperature storage up to 77°F1,c |
|
|
|
| Available in 1-mg, 2-mg, 5-mg, and 8-mg vials1 |
|
|
|
| Everything needed for reconstitution is in 1 box with a prefilled syringe1,d |
|
|
|
|
| aIndicated for bleed control and surgery in 4 bleeding disorders: CHAwI or CHBwI, AH, CFVIId, and GT.1 |
| bIn patients with hemophilia A or B with inhibitors; individual doses for a joint bleed are compared and based on an 88-kg (194-lb) person. |
| cPrior to reconstitution, store NovoSeven® RT powder and histidine diluent between 36-77°F. After reconstitution, store NovoSeven® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven® RT or store in syringes.1 |
| dCompared with reconstitution using histidine vials.1 |
|
|
| Keep scrolling to learn more about NovoSeven® RT education and resources |
 |
|
| Selected Important Safety Information |
| WARNING: THROMBOSIS |
| • |
Serious arterial and venous thrombotic events following administration
of NovoSeven® RT have been reported
|
|
| • |
Discuss the risks and explain the signs and symptoms of thrombotic and
thromboembolic events to patients who will receive
NovoSeven® RT
|
|
| • |
Monitor patients for signs or symptoms of activation of the coagulation
system and for thrombosis
|
|
|
| Warnings and Precautions |
| • |
Serious arterial and venous thrombotic events have been reported in clinical trials
and postmarketing surveillance
|
|
| • |
Patients with congenital hemophilia receiving concomitant treatment with aPCCs
(activated prothrombin complex concentrates), older patients particularly with
acquired hemophilia and receiving other hemostatic agents, and patients with a
history of cardiac and vascular disease may have an increased risk of developing
thrombotic events
|
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
|
| When every second counts, keep these dosing resources at your fingertips |
| Your team relies on your expertise to help them quickly and effectively treat patients with rare bleeding disorders. In addition to quick-reference dosing and administration information, novoMEDLINK™ includes helpful resources like the dosing calculator*, so you can get immediate, reliable information anytime, anywhere. |
| *For US healthcare professionals only. |
|
|
|
|
| Have you created an account on novoMEDLINK™? |
 |
| Keep up with important information about treatments for rare bleeding disorders. |
| Receive the latest news about rare bleeding disorders from Novo Nordisk. |
| Download, order, and share educational materials for you and your patients. |
|
|
|
|
| Indications and Usage |
|
NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor
indicated for:
|
| • |
Treatment of bleeding episodes and perioperative management in adults and children
with hemophilia A or B with inhibitors, congenital Factor VII (FVII)
deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet
transfusions, with or without antibodies to platelets
|
|
| • |
Treatment of bleeding episodes and perioperative management in adults with acquired
hemophilia
|
|
| Important Safety Information (cont’d) |
| Warnings and Precautions |
| • |
Hypersensitivity reactions, including anaphylaxis, can occur with
NovoSeven® RT. Patients with a known hypersensitivity to mouse,
hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions.
Discontinue infusion and administer appropriate treatment when hypersensitivity
reactions occur
|
|
| • |
Factor VII deficient patients should be monitored for prothrombin time (PT) and
factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level,
or PT is not corrected, or bleeding is not controlled after treatment with the
recommended doses, antibody formation may be suspected and analysis for antibodies
should be performed
|
|
| • |
Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct
correlation to achieving hemostasis
|
|
| Adverse Reactions |
| • |
The most common and serious adverse reactions in clinical trials are thrombotic
events. Thrombotic adverse reactions following the administration of
NovoSeven® RT in clinical trials occurred in 4% of patients with
acquired hemophilia and 0.2% of bleeding episodes in patients with congenital
hemophilia
|
|
| Drug Interactions |
| • |
Thrombosis may occur if NovoSeven® RT is administered
concomitantly with Coagulation Factor XIII
|
|
|
Please click here for
Prescribing Information, including Boxed Warning.
|
|
|
| 1. |
NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020. |
| 2. |
Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia. 2007;13(5):527-532. |
| 3. |
FEIBA [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2020. |
| 4. |
OBIZUR [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2021. |
| 5. |
SEVENFACT [package insert]. Louisville, KY: HEMA Biologics; 2020. |
|
|
<%@ include view='hcpColoradoFooter' %>
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2022 Novo Nordisk All rights reserved. US22NSVN00055 September 2022 |
 |
|
|
|